Klinická farmakologie a farmacie

KLINICKÁ FARMAKOLOGIE A FARMACIE / Klin Farmakol Farm 2020; 34(2): 84–88 / www.klinickafarmakologie.cz 88 PŘEHLEDOVÉ ČLÁNKY Nová přímá perorální antikoagulancia – nové molekuly ve výzkumu LITERATURA 1. Burdová K. Přímá perorální antikogulancia. Klin Farmakol Farm. 2015, 29(4): 138–143. 2. Zatloukalová A, Janoutová J, Homza M, Janout V. Epide miologická studie nových perorálních antikoagulancií. Klin Farmakol Farm. 2018, 32(2), 3–7. 3. Kvasnička J, Penka M, Kvasnička T, a kol. Doporučení české společnosti pro trombózu a hemostázu České lékařské spo lečnosti J. E. Purkyně pro bezpečnou léčbu novými perorál ními antikoagulancii (NOAC) – dabigatran exilátem, apixa banem a rivaroxabanem. Vnitř. Lék. 2015; 61(6): 537–546. 4. Connolly SJ, Crowther M, Eikelboom JW, et al. Full Stu dy Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors. New England Journal of Medicine [on line]. 2019 [cit. 2019–03–26]. DOI: 10.1056/NEJMoa1814051. ISSN 0028–4793. Dostupné z: http://www.nejm.org/ doi/10.1056/NEJMoa1814051 5. Karetová D, Bultas J. Řešení urgentních stavů spojených s rizikem krvácení u nemocných užívajících nová perorál ní antikoagulancia – možnosti ukončení účinku. Remedia. 26(2): 235–140. 6. Ramacciotti E, Hoppensteadt D, Fareed J. Betrixaban for VTE Prevention in the Medically Ill Population, the APEX Trial: Good News for This Needy Population?. Clinical and Applied Thrombosis/Hemostasis [online]. 2016, 23(7), 701– 702 [cit. 2019–02–25]. DOI: 10.1177/1076029616683805. ISSN 1076–0296. Dostupné z: http://journals.sagepub.com/ doi/10.1177/1076029616683805 7. Skelley J, Thomason A, Nolen J. Betrixaban (Bevyxxa): A Direct‑Acting Oral Anticoagulant Factor Xa Inhibitor. P & T : a peer‑reviewed journal for formulary management [onli ne]. 2018, 43(2), 85–120 [cit. 2019–02–25]. Dostupné z: https:// www.ncbi.nlm.nih.gov/pmc/articles/PMC5768296/ 8. Dobesh PP, Trevarrow BJ. Betrixaban: Safely Reducing Ve nous Thromboembolic Events with Extended Prophylaxis. The American Journal of Medicine [online]. 2018 [cit. 2019– 02–25]. DOI: 10.1016/j.amjmed.2018. 08. 024. ISSN 00029343. Dostupné z: https://linkinghub.elsevier.com/retrieve/pii/ S0002934318308520 9. Lekura J, Kalus JS. Overview of betrixaban and its role in clinical practice. American Journal of Health‑System Phar macy[online]. 2018, 75(15), 1095–1102 [cit. 2019–02–25]. DOI: 10.2146/ajhp170785. ISSN 1079–2082. Dostupné z: https://aca demic.oup.com/ajhp/article/75/15/1095/5102024 10. Beyer‑Westendorf J, Verhamme P, Bauersachs R. Betrixa ban for prevention of venous thromboembolism in acute me dically ill patients. European Heart Journal Supplements [onli ne]. 2018, 20(suppl E), E16-E22 [cit. 2019–02–25]. DOI: 10.1093/ eurheartj/suy017. ISSN 1520–765X. Dostupné z: https://acade mic.oup.com/eurheartjsupp/article/20/suppl_E/E16/4993363 11. Iwatsuki Y, Sato T, Moritani Y, Shigenaga T, et al. Biochemi cal and pharmacological profile of darexaban, an oral direct factor Xa inhibitor. European Journal of Pharmacology[onli ne]. 2011, 673(1–3), 49–55 [cit. 2019–03–19]. DOI: 10.1016/j.ej phar.2011. 10. 009. ISSN 00142999. Dostupné z: https://linkin ghub.elsevier.com/retrieve/pii/S0014299911012398 12. Kaku S, Suzuki M, Saitoh M, Funatsu T, et al. Darexaban: Anticoagulant effects in mice and human plasma in vitro, antithrombotic effects in thrombosis and bleeding mo dels in mice and effects of anti‑inhibitor coagulant com plex and recombinant factor VIIa. Thrombosis Research [on line]. 2013, 131(5), 450–456 [cit. 2019–03–19]. DOI: 10.1016/j. thromres.2013. 03. 016. ISSN 00493848. Dostupné z: https:// linkinghub.elsevier.com/retrieve/pii/S0049384813001035 13. Kadokura T, Kashiwa M, Groenendaal D, Heeringa M, et al. Clinical pharmacokinetics, pharmacodynamics, safety and tolerability of darexaban, an oral direct factor Xa inhibitor, in healthy Caucasian and Japanese subjects. Biopharma ceutics & Drug Disposition [online]. 2013, 34(8), 431–441 [cit. 2019–03–19]. DOI: 10.1002/bdd.1858. ISSN 01422782. Dostup né z: http://doi.wiley.com/10.1002/bdd.1858 14. Hashimoto T, Suzuki K, Kihara Y, et al. Absorption, metabo lism and excretion of darexaban (YM150), a new direct factor Xa inhibitor in humans. Xenobiotica [online]. 2012, 43(6), 534– 547 [cit. 2019–03–19]. DOI: 10.3109/00498254.2012.738045. ISSN 0049–8254. Dostupné z: http://www.tandfonline.com/ doi/full/10.3109/00498254.2012.738045 15. Kadokura T, Groenendaal D, Heeringa M, Mol R, et al. Darexaban (YM150), an oral direct factor Xa inhibitor, has no effect on the pharmacokinetics of digoxin. European Journal of Drug Metabolism and Pharmacokinetics [online]. 2014, 39(1), 1–9 [cit. 2019–03–19]. DOI: 10.1007/s13318–013– 0141–1. ISSN 0378–7966. Dostupné z: http://link.springer. com/10.1007/s13318–013–0141–1 16. Kadokura T, Taniuchi Y, Inoue H, Saito M, et al. Effect of food on the pharmacokinetics of darexaban, an oral direct factor Xa inhibitor, in healthy Japanese subjects. Int. Journal of Clinical Pharmacology and Therapeutics [online]. 2013, 51(03), 200–206 [cit. 2019–03–19]. DOI: 10.5414/CP201804. ISSN 0946–1965. Dostupné z: http://www.dustri.com/ar ticle_response_page.html?artId=10188 & doi=10.5414/ CP201804 & L=0 17. Eriksson B I, Turpie AGG, Lassen MR, et al. Prevention of venous thromboembolism with an oral factor Xa inhibi tor, YM150, after total hip arthroplasty. A dose finding stu dy (ONYX-2). Journal of Thrombosis and Haemostasis [on line]. 2010, 8(4), 714–721 [cit. 2019–03–20]. DOI: 10.1111/j. 1538–7836.2010.03748.x. ISSN 15387933. Dostupné z: http:// doi.wiley.com/10.1111/j.1538–7836.2010.03748.x 18. Steg Ph.G, Mehta SR, Jukema JW, et al. RUBY-1: a rando mized, double‑blind, placebo‑controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexa ban (YM150) following acute coronary syndrome. European Heart Journal [online]. 2011, 32(20), 2541–2554 [cit. 2019–03– 20]. DOI: 10.1093/eurheartj/ehr334. ISSN 0195–668X. Dostup né z: https://academic.oup.com/eurheartj/article‑lookup/ doi/10.1093/eurheartj/ehr334 19. Sakon M, Nakamura M. Darexaban (YM150) prevents venous thromboembolism in Japanese patients undergo ing major abdominal surgery: Phase III randomized, me chanical prophylaxis‑controlled, open‑label study. Throm bosis Research [online]. 2012, 130(3), e52-e59 [cit. 2019–03– 20]. DOI: 10.1016/j.thromres.2012. 06. 009. ISSN 00493848. Dostupné z: https://linkinghub.elsevier.com/retrieve/pii/ S0049384812002800 20. Gómez‑Outes A, Suárez‑Gea ML, Lecumberri R, Rocha E, at al. New parenteral anticoagulants in development. The rapeutic Advances in Cardiovascular Disease[online]. 2011, 5(1), 33–59 [cit. 2019–03–25]. DOI: 10.1177/1753944710387808. ISSN 1753–9447. Dostupné z: http://journals.sagepub.com/ doi/10.1177/1753944710387808 21. Hinder M, Frick A, Jordaan P, Hesse G, et al. Direct and ra pid inhibition of factor Xa by otamixaban: A pharmacokinetic and pharmacodynamic investigation in patients with corona ry artery disease. Clinical Pharmacology & Therapeutics[on line]. 2006, 80(6), 691–702 [cit. 2019–03–25]. DOI: 10.1016/j. clpt.2006. 09. 002. ISSN 00099236. Dostupné z: http://doi. wiley.com/10.1016/j.clpt.2006. 09. 002 22. Cohen M, Bhatt DL, Alexander JH, et al. Randomized, Double‑Blind, Dose‑Ranging Study of Otamixaban, a No vel, Parenteral, Short‑Acting Direct Factor Xa Inhibitor, in Percutaneous Coronary Intervention. Circulation [online]. 2007, 115(20), 2642–2651 [cit. 2019–03–25]. DOI: 10.1161/CIR CULATIONAHA.106.653428. ISSN 0009–7322. Dostupné z: https://www.ahajournals.org/doi/10.1161/CIRCULATIONA HA.106.653428 23. Sabatine MS, EM Antman, Widimsky P, et al. Otamixaban for the treatment of patients with non‑ST‑elevation acute coronary syndromes (SEPIA‑ACS1 TIMI 42): a randomised, double‑blind, active‑controlled, phase 2 trial. The Lancet [on line]. 2009, 374(9692), 787–795 [cit. 2019–03–25]. DOI: 10.1016/ S0140–6736(09)61454–9. ISSN 01406736. Dostupné z: https:// linkinghub.elsevier.com/retrieve/pii/S0140673609614549 24. Dillinger J‑G, Gregory DUCROCQ, Elbez Y, et al. Acti vated Clotting Time to Guide Heparin Dosing in Non–ST ‑Segment–Elevation Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention and Trea ted With IIb/IIIa Inhibitors. Circulation: Cardiovascular Inter ventions [online]. 2018, 11(6) [cit. 2019–03–26]. DOI: 10.1161/ CIRCINTERVENTIONS.118.006084. ISSN 1941–7640. Dostup né z: https://www.ahajournals.org/doi/10.1161/CIRCINTER VENTIONS.118.006084 25. Deharo P, Ducrocq G, Bode CH, et al. Timing of Angio graphy and Outcomes in High‑Risk Patients With Non–ST ‑Segment–Elevation Myocardial Infarction Managed In vasively. Circulation [online]. 2017, 136(20), 1895–1907 [cit. 2019–03–26]. DOI: 10.1161/CIRCULATIONAHA.117.029779. ISSN 0009–7322. Dostupné z: https://www.ahajournals.org/ doi/10.1161/CIRCULATIONAHA.117.029779 26. Steg PG. Anticoagulation With Otamixaban and Ische mic Events in Non–ST‑Segment Elevation Acute Coronary Syndromes. JAMA [online]. 2013, 310(11) [cit. 2019–03–26]. DOI: 10.1001/jama.2013.277165. ISSN 0098–7484. Dostupné z: http://jama.jamanetwork.com/article.aspx?doi=10.1001/ jama.2013.277165 27. Dhakal P. Rayamajhi S, Verma V, Gundabolu K, Bhatt VR. Reversal of Anticoagulation and Management of Bleeding in Patients on Anticoagulants. Clinical and Applied Thrombo sis/Hemostasis [online]. 2016, 23(5), 410–415 [cit. 2019–03–27]. DOI: 10.1177/1076029616675970. ISSN 1076–0296. Dostupné z: http://journals.sagepub.com/doi/10.1177/1076029616675970 28. Levy JH, Douketis J, Weitz JI. Reversal agents for non ‑vitamin K antagonist oral anticoagulants. Nature Reviews Cardiology [online]. 2018, 15(5), 273–281 [cit. 2019–03–27]. DOI: 10.1038/nrcardio.2017.223. ISSN 1759–5002. Dostupné z: http://www.nature.com/doifinder/10.1038/nrcardio.2017.223 29. Crowther M, Cuker A. How can we reverse bleeding in patients on direct oral anticoagulants? Kardiologia Polska [online]. 2019, 77(1), 3–11 [cit. 2019–03–27]. DOI: 10.5603/ KP.a2018.0197. ISSN 1897–4279. Dostupné z: https://ojs.kar diologiapolska.pl/kp/article/view/12634 30. Ansell JE, Bakhru SH, Laulicht BE, et al. Single‑dose ci raparantag safely and completely reverses anticoagulant effects of edoxaban. Thrombosis and Haemostasis [online]. 2017, 117(02), 238–245 [cit. 2019–03–27]. DOI: 10.1160/TH16– 03–0224. ISSN 0340–6245. Dostupné z: http://www.thieme ‑connect.de/DOI/DOI?10.1160/TH16–03–0224 31. Dabi A, Koutrouvelis AP. Reversal Strategies for Intra cranial Hemorrhage Related to Direct Oral Anticoagulant Medications. Critical Care Research and Practice [online]. 2018, 2018, 1–11 [cit. 2019–03–27]. DOI: 10.1155/2018/4907164. ISSN 2090–1305. Dostupné z: https://www.hindawi.com/jour nals/ccrp/2018/4907164/ 32. Riley TR, Gauthier‑Lewis ML, Sanchez CHK, DOUGLAS JS. Role of agents for reversing the effects of target‑specific oral anticoagulants. American Journal of Health‑System Pharma cy [online]. 2017, 74(2), 54–61 [cit. 2019–03–27]. DOI: 10.2146/ ajhp150810. ISSN 1079–2082. Dostupné z: https://academic. oup.com/ajhp/article/74/2/54/5102888

Klinická farmakologie a farmacie – 2/2020